| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Carpaloliganin A (compound 1) (24–48 hours) exhibits larval-killing activity against third-instar Aedes aegypti larvae with an LC50 value of 71.14 ppm [1]. Carpaloliganin A (71.14 ppm; 24 hours) reduces the activity of glutathione-S-transferase in surviving third-instar Aedes aegypti larvae [1]. Carpaloliganin A (0–400 μg/mL; 72 hours) inhibits the replication of influenza A virus strain A/PR/8/34 (H1N1) in MDCK cells with an IC50 value of 115.25 μg/mL [2]. Carpaligrin A (48 h) showed potent antiviral activity against human influenza virus subtypes A/PR/8/34 (H1N1), A/GZ/GIRD07/09 (H1N1 pdm2009) and A/HK/8/68 (H3N2) in MDCK cells, with IC50 values of 288.03, 362.18 and 375.73 μg/mL, and SI values of 4.36, 3.37 and 3.34, respectively [2]. Carpaligrin A showed antiviral activity against parainfluenza virus type 3 (PIV3) in LLC-MK2 cells (IC50 = 757.86 μg/mL, SI = 1.32) and antiviral activity against adenovirus type 3 (ADV3) in A549 cells (IC50 = 382.23 μg/mL, SI = 3.32) [2]. Caparidine A (0–4 mg/mL; 6–72 h) inhibited progeny replication of influenza A virus A/PR/8/34 (H1N1) strain in 16HBE cells and suppressed virus-induced expression of IL-6, IP-10, MCP-1, and RANTES/CCL-5 at doses as low as 0.25 mg/mL [2]. Caparidine A (0.25–2 mg/mL; 24, 48 h) inhibited progeny replication of influenza A virus A/PR/8/34 (H1N1) strain in RAW264.7 cells and suppressed virus-induced expression of IP-10 and RANTES/CCL-5 at concentrations of 1 mg/mL and 0.5 mg/mL [2]. Carpaliglucoside A (0–1 mg/mL; 24 h) inhibited the expression of IP-10 and RANTES/CCL-5 in 16HBE cells induced by avian influenza virus H9N2, but did not inhibit viral replication [2]. Carpaliglucoside A (0–2 mg/mL; 24 h) inhibited the expression of IP-10, IL-6 and RANTES/CCL-5 in RAW264.7 cells induced by LPS, without affecting TNF-α levels [2]. Carpaliglucoside A (0–2 mg/mL; 6, 24, 48, 72 h) regulated the host IFN signaling pathway in 16HBE cells by inhibiting virus-induced STAT1 phosphorylation, reducing the expression of IFN-β and IL-29, and inhibiting the expression of IP-10 and RANTES/CCL-5 induced by IFN-β [2].
|
|---|---|
| ln Vivo |
Carparibine A (75-300 mg/kg/day; orally; twice daily for 5 days) dose-dependently inhibited influenza-induced inflammation and lung injury in female BALB/c mice [2].
|
| Cell Assay |
ELISA detection [2]
Cell Types: Human bronchial epithelial cells (16HBE) infected with avian influenza virus A/Chicken/Guangdong/1996 (H9N2) Tested Concentrations: 1, 0.5, 0.25 mg/mL Incubation Duration: 24 hours Experimental Results: Although it did not inhibit H9N2 replication, it significantly reduced H9N2-induced IP-10 and RANTES/CCL-5 protein levels in a dose-dependent manner. ELISA detection [2] Cell Types: Lipopolysaccharide (LPS) stimulated mouse macrophages (RAW264.7) Tested Concentrations: 2, 1 mg/mL Incubation Duration: 24 hours Experimental Results: Significantly reduced LPS-induced IP-10, IL-6 and RANTES/CCL-5 protein levels in a dose-dependent manner, with no effect on TNF-α levels. |
| Animal Protocol |
Animal/Disease Models:BALB/c (female, 6-8 weeks old) [2]
Doses: 75-300 mg/kg/day Route of Administration: Oral; twice daily for 5 days Experimental Results: The 300 mg/kg/day dose group suppressed influenza-induced weight loss on days 3, 5, and 7 post-infection; the 150 and 75 mg/kg/day dose groups suppressed influenza-induced weight loss on day 3 post-infection. The 300 mg/kg/day dose group reduced the lung index by 50% on day 5 post-infection; the 150 mg/kg/day dose group reduced the lung index by 30% on day 5 post-infection; and the lung index was reduced by 20% on day 5 post-infection at a dose of 75 mg/kg/day. On days 3, 5, and 7 post-infection, administration of 300 mg/kg/day inhibited the increase in total protein concentration in bronchoalveolar lavage fluid (BALF); on days 3, 5, and 7 post-infection, administration of 150 mg/kg/day inhibited the increase in total protein concentration in BALF; and on days 3 and 5 post-infection, administration of 75 mg/kg/day inhibited the increase in total protein concentration in BALF. Administration of 300 mg/kg/day reduced inflammatory cell infiltration, inflammatory area, and pathological score in lung tissue. On day 5 post-infection, administration of 300, 150, and 75 mg/kg/day all reduced the total white blood cell count in BALF. At days 3, 5, and 7 post-infection, a dose of 300 mg/kg/day inhibited influenza-induced IL-6 and IP-10 levels in BALF; at days 3 and 5 post-infection, doses of 150 and 75 mg/kg/day, respectively, inhibited influenza-induced IL-6 and IP-10 levels in BALF. |
| References |
|
| Molecular Formula |
C16H18N2O6
|
|---|---|
| Molecular Weight |
334.32
|
| CAS # |
229483-41-4
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
N#CCC1=CNC2=CC=CC(O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)=C21
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9911 mL | 14.9557 mL | 29.9115 mL | |
| 5 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL | |
| 10 mM | 0.2991 mL | 1.4956 mL | 2.9911 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
